Kuros Biosciences AG
CSBTFOTCHealthcare● Active
$26.00
+$1.25(+5.05%)
Market Cap$1.0B
P/E Ratio—
52W High$42.81
52W Low$24.75
Kuros Biosciences AG (CSBTF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CSBTF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.12B | $0.08B | $0.03B | $0.02B | $0.01B |
| Cost of Revenue | $0.02B | $0.01B | $0.01B | $0.01B | $0.00B |
| Gross Profit | $0.10B | $0.06B | $0.03B | $0.01B | $0.01B |
| Gross Margin %(computed) | 86.39% | 82.10% | 84.83% | 59.87% | 72.86% |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.00B |
| G&A Expenses | $0.00B | $0.01B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.10B | $0.07B | $0.04B | $0.02B | $0.02B |
| Operating Income | $0.01B | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Operating Margin %(computed) | 6.04% | -6.61% | -39.30% | -74.76% | -63.46% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Income Before Tax | $0.00B | ($0.00B) | ($0.01B) | ($0.02B) | ($0.01B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | ($0.00B) | ($0.00B) |
| Net Income | $0.00B | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Net Margin %(computed) | 1.75% | -4.92% | -40.90% | -81.15% | -54.59% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.06 | $-0.10 | $-0.38 | $-0.43 | $-0.23 |
| Wtd Avg Shares | 0.04B | 0.04B | 0.04B | 0.03B | 0.03B |
| EBITDA | $0.01B | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) |
| EBITDA Margin %(computed) | 8.35% | -0.74% | -22.33% | -41.70% | -38.30% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CHF · B
Explore more Kuros Biosciences AG data
About Kuros Biosciences AG (CSBTF) Income Statement
Kuros Biosciences AG (CSBTF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CSBTF reported revenue of $0.12B, gross profit of $0.10B (gross margin 86.39%), and net income of $0.00B — a net profit margin of 1.75%.
Frequently asked questions
CSBTF · 4 questionsKuros Biosciences AG (CSBTF) reported revenue of $0.12B for 2025, up 60.6% year-over-year.
CSBTF revenueCSBTF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09